In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SkelRegen LLC

www.skelregen.com

Latest From SkelRegen LLC

Regenerating Interest In Novel Drugs For Postmenopausal Osteoporosis

New bone-targeted agents for osteoporosis must clear significant obstacles to succeed in a highly generic market, but safety concerns with established agents like bisphosphonates and calcitonin offer a foothold. Phase III anabolic candidates from Amgen and Radius Health aim to build new bone, the holy grail of osteoporosis treatment, but R&D in new anti-resorptive mechanisms to halt bone breakdown also continues.

BioPharmaceutical Clinical Trials

Out Of The Blocks, November 2012

Brief profiles of these recently formed companies: ABK Biomedical, LuxCath, Quantamerix, SkelRegen, Thesan Pharmaceuticals, and Ziarco Pharma.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • SkelRegen LLC
  • Senior Management
  • Scott D Boden, MD, Chief Medical & Technology Office
  • Contact Info
  • SkelRegen LLC
    Phone: (610) 314-3938
    929 South High St.
    Ste. 195
    West Chester, PA 19382
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register